Carmenta gains licensing option for preeclampsia diagnostic tool

01/28/2013 | GenomeWeb Daily News (free registration)

Carmenta Bioscience has been granted an option to exclusively license technology from Stanford University for undisclosed terms. The Palo Alto, Calif.-based company aims to use the technology to design assays for detecting preeclampsia in pregnant women with or without symptoms of the illness, President and CEO Matthew Cooper said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT